Eliem Therapeutics Stock Price, News & Analysis (NASDAQ:ELYM) $2.57 -0.03 (-1.15%) (As of 11/29/2023 ET) Add Compare Share Share Today's Range$2.52▼$2.6150-Day Range$2.45▼$2.6852-Week Range$2.21▼$4.75Volume800 shsAverage Volume19,544 shsMarket Capitalization$70.85 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Eliem Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside129.9% Upside$6.00 Price TargetShort InterestHealthy0.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.22 out of 5 starsMedical Sector684th out of 949 stocksPharmaceutical Preparations Industry332nd out of 436 stocks 3.0 Analyst's Opinion Consensus RatingEliem Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Eliem Therapeutics has a forecasted upside of 129.9% from its current price of $2.61.Amount of Analyst CoverageEliem Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.19% of the float of Eliem Therapeutics has been sold short.Short Interest Ratio / Days to CoverEliem Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eliem Therapeutics has recently decreased by 14.94%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEliem Therapeutics does not currently pay a dividend.Dividend GrowthEliem Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELYM. Previous Next 3.0 News and Social Media Coverage News SentimentEliem Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Eliem Therapeutics this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eliem Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Eliem Therapeutics is held by insiders.Percentage Held by Institutions61.78% of the stock of Eliem Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Eliem Therapeutics is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eliem Therapeutics is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEliem Therapeutics has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Eliem Therapeutics Stock (NASDAQ:ELYM)Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.Read More ELYM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELYM Stock News HeadlinesNovember 19, 2023 | morningstar.comCheckpoint Therapeutics Inc CKPTNovember 15, 2023 | morningstar.comEliem Therapeutics Inc ELYMNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comSeptember 28, 2023 | finance.yahoo.comEliem Therapeutics (NASDAQ:ELYM) Is In A Good Position To Deliver On Growth PlansJuly 21, 2023 | finance.yahoo.comEliem (ELYM) to Explore Strategic Options, Stock Rises 6%July 21, 2023 | msn.comEliem Therapeutics’ stock soars 21% premarket after company says it may sell itselfJuly 20, 2023 | benzinga.comWhat's Happening With Eliem Therapeutics Shares Today?July 20, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Announces Plans to Explore Strategic AlternativesNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comJuly 20, 2023 | marketwatch.comEliem Therapeutics Shares Rally Premarket on Exploration of Options >ELYMJuly 20, 2023 | markets.businessinsider.comWhy Is Eliem Therapeutics (ELYM) Stock Up 6% Today?July 20, 2023 | finance.yahoo.comEliem Therapeutics Announces Plans to Explore Strategic AlternativesJune 7, 2023 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Eliem Therapeutics (ELYM)May 25, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Eliem Therapeutics (ELYM)May 12, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Reports First Quarter Financial Results and Business HighlightsMay 11, 2023 | seekingalpha.comEliem Therapeutics GAAP EPS of -$0.84May 11, 2023 | finance.yahoo.comEliem Therapeutics Reports First Quarter Financial Results and Business HighlightsApril 21, 2023 | finance.yahoo.comWe're Hopeful That Eliem Therapeutics (NASDAQ:ELYM) Will Use Its Cash WiselyMarch 9, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Eliem Therapeutics (ELYM)March 7, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business HighlightsMarch 6, 2023 | finance.yahoo.comEliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business HighlightsFebruary 23, 2023 | seekingalpha.comELYM Eliem Therapeutics, Inc.February 23, 2023 | finance.yahoo.comEliem Therapeutics slashing staff amid leadership shakeupFebruary 18, 2023 | finance.yahoo.comEliem Pauses Development On Depression Drug, Lays Off 55% WorkforceFebruary 10, 2023 | msn.comEliem Therapeutics down after announcing reprioritization plans, layoffsFebruary 9, 2023 | finance.yahoo.comEliem Therapeutics Provides Strategic Update and Announces Leadership TransitionNovember 30, 2022 | finance.yahoo.comEliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual ConferenceSee More Headlines Receive ELYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ELYM CUSIPN/A CIK1768446 Webwww.eliemtx.com Phone877-354-3689FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+138.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.55% Return on Assets-32.29% Debt Debt-to-Equity RatioN/A Current Ratio38.76 Quick Ratio38.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.98 per share Price / Book0.63Miscellaneous Outstanding Shares27,570,000Free Float26,691,000Market Cap$69.48 million OptionableNot Optionable Beta0.40 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Andrew Levin M.D. (Age 46)Ph.D., Principal Financial Officer & Executive Chairman Comp: $73kDr. Valerie Morisset Ph.D. (Age 53)Chief Scientific Officer and Executive VP of Research & Development Comp: $617.87kMs. Emily Pimblett (Age 39)Principal Accounting Officer Ms. Jo Palmer-Phillips Ph.D.Chief Development OfficerKey CompetitorsNektar TherapeuticsNASDAQ:NKTRGraphite BioNASDAQ:GRPHSelecta BiosciencesNASDAQ:SELBGeneluxNASDAQ:GNLXKronos BioNASDAQ:KRONView All CompetitorsInstitutional OwnershipSilverarc Capital Management LLCSold 372,979 shares on 11/13/2023Ownership: 0.447%BML Capital Management LLCBought 355,093 shares on 10/23/2023Ownership: 7.155%View All Institutional Transactions ELYM Stock Analysis - Frequently Asked Questions Should I buy or sell Eliem Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eliem Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ELYM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ELYM, but not buy additional shares or sell existing shares. View ELYM analyst ratings or view top-rated stocks. What is Eliem Therapeutics' stock price target for 2024? 1 Wall Street analysts have issued 12-month price objectives for Eliem Therapeutics' stock. Their ELYM share price targets range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 129.9% from the stock's current price. View analysts price targets for ELYM or view top-rated stocks among Wall Street analysts. How have ELYM shares performed in 2023? Eliem Therapeutics' stock was trading at $3.67 at the beginning of 2023. Since then, ELYM stock has decreased by 28.9% and is now trading at $2.61. View the best growth stocks for 2023 here. Are investors shorting Eliem Therapeutics? Eliem Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 35,300 shares, a decrease of 14.9% from the October 31st total of 41,500 shares. Based on an average daily volume of 15,100 shares, the short-interest ratio is currently 2.3 days. Approximately 0.2% of the shares of the stock are short sold. View Eliem Therapeutics' Short Interest. When is Eliem Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our ELYM earnings forecast. How were Eliem Therapeutics' earnings last quarter? Eliem Therapeutics, Inc. (NASDAQ:ELYM) announced its earnings results on Monday, November, 8th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.19. When did Eliem Therapeutics IPO? (ELYM) raised $75 million in an IPO on Tuesday, August 10th 2021. The company issued 6,000,000 shares at $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities served as the underwriters for the IPO. Who are Eliem Therapeutics' major shareholders? Eliem Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BML Capital Management LLC (7.15%) and Silverarc Capital Management LLC (0.45%). How do I buy shares of Eliem Therapeutics? Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ELYM) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.